01
Scored against your profile.
Criteria come from your target product profile's endpoints, so the competitive landscape is measured on what matters for your asset, not on a generic checklist.
Know where you win
Know where you win, and keep knowing
A pharma competitive assessment that scores your asset against every relevant competitor on clinical, commercial, government and manufacturing criteria drawn from your own target profile. Differentiation you can prove, not assert.
vs Minimum4.8
vs Base5.1
vs Upside5.4
02
A clear verdict.
Better, Undifferentiated or Worse for each comparison, stamped with the date your profile last changed. The debate moves from "are we different?" to "what do we do about it?".
vs Programme NB-401 · Phase IIIBetter
vs Programme VX-12 · Phase IIUndifferentiated
vs Programme KL-7 · ApprovedWorse
03
When the market moves, so does your case.
Update a competitor or your profile and see the effect on your verdicts, then on your market share, your forecast and your value.
vs Programme VX-12
TPP last updated 12 Jun 2026
Verdict
Undifferentiated
Coming soon
- Alerts when a new trial or regulatory signal affects a competitive score, forecast or value
One connected case
Your differentiation feeds your market share, and your market share feeds your value.
FAQ
Questions about differentiation
Which dimensions are scored?
Four: clinical, commercial, government and manufacturing. Each carries criteria and a confidence level.
Where do the criteria come from?
From the endpoints in your target product profile. Each competitor is scored against your Minimum, Base and Upside profile.
Can we add our own competitors?
Yes. You track the programmes that matter to your asset across the landscape, by development stage.
How do we keep it current?
Each comparison shows when your profile last changed, so the team can see which verdicts need a fresh look. Updating a competitor or your profile carries through to verdicts, share and value.